CEL-SCI Corporation (CVM)
- Previous Close
1.4500 - Open
1.4700 - Bid 1.4000 x 800
- Ask 1.4600 x 1000
- Day's Range
1.3900 - 1.4800 - 52 Week Range
1.0400 - 3.2300 - Volume
135,955 - Avg. Volume
306,633 - Market Cap (intraday)
77.73M - Beta (5Y Monthly) 1.17
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6900 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Aug 28, 1996
- 1y Target Est
8.47
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
cel-sci.comRecent News: CVM
Performance Overview: CVM
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CVM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CVM
Valuation Measures
Market Cap
77.73M
Enterprise Value
87.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.14
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.32
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-51.71%
Return on Equity (ttm)
-158.25%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-31.05M
Diluted EPS (ttm)
-0.6900
Balance Sheet and Cash Flow
Total Cash (mrq)
3.26M
Total Debt/Equity (mrq)
103.55%
Levered Free Cash Flow (ttm)
-9.52M